Leading American CBD producer Charlotte’s Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) is launching a line of health-focused gummies with supplement retail powerhouse GNC across the U.S.
On Tuesday, the Denver, Colorado-based cannabis company said an initial shipment of six gummy varieties will be in GNC stores across 24 states, with the intent to expand.
To best reach and serve consumers, Charlotte’s Web relies in part on strong partnership with proven mass retail partners, CEO Jacques Tortoroli says in a statement.
“GNC’s established retail footprint adds depth to our reach domestically and broadens consumer access to our high-quality hemp CBD products,” he says.
“We expect GNC will become one of our largest retail customers this year, and we are excited about the growth provided by bringing our two leading brands together.”
According to GNC’s website, it has over 4,800 retail locations in America, with franchise operations in 46 international markets.
The gummies are made with “full-spectrum” hemp extracts from its patented hemp cultivars. They’re vegan and non-GMO, featuring low concentrations of CBD with terpenes, flavonoids and other “beneficial” hemp compounds.
The products will feature other nutritional supplements to meet various wellness needs.
The six formulations include a raspberry-flavoured Sleep gummy with 10 milligrams of CBD and 3 milligrams of melatonin; a lemon berry-flavoured Immunity gummy with 10 milligrams of CBD, 90 milligrams of vitamin C and 70 milligrams of astragalus root; and a mango peach-flavoured THC-Free gummy with 15 milligrams of CBD “to support everyday wellness, whether on the job or at home.”
While major firms like Canopy Growth Corporation (TSX: WEED) (Nasdaq: CGC) and Aurora Cannabis Inc. (TSX: ACB) have launched a number of CBD-based products in the U.S., the country has yet to approve a bill that regulates goods containing the cannabinoid.
Read more: Another bipartisan bill seeks to regulate CBD in US
Read more: US Senate bill would finally allow CBD in food and drinks
Another bipartisan effort to approve legislation kicked off in December, to put an end to the regulatory grey area.
The FDA has been promising a speedy process to create rules for CBD since 2019.